Evidence map›Paper›PMID 23777698›Full record

ReviewVaccine2013

Cost analysis of an integrated vaccine-preventable disease surveillance system in Costa Rica.

C M Toscano, M Vijayaraghavan, H M Salazar-Bolaños, H M Bolaños-Acuña, A I Ruiz-González, T Barrantes-Solis, I Fernández-Vargas, M S Panero, L H de Oliveira, T B Hyde and 1 more

Abstract readReview
In one paragraph

Review in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

C M ToscanoDepartment of Community Health, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Goiás, Brazil. ctoscano@terra.com.br
M Vijayaraghavan
H M Salazar-Bolaños
H M Bolaños-Acuña
A I Ruiz-González
T Barrantes-Solis
I Fernández-Vargas
M S Panero
L H de Oliveira
T B Hyde
iVPD Working Team

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

introductionFollowing World Health Organization recommendations set forth in the Global Framework for Immunization Monitoring and Surveillance, Costa Rica in 2009 became the first country to implement integrated vaccine-preventable disease (iVPD) surveillance, with support from the U.S. Centers for Disease Control and Prevention (CDC) and the Pan American Health Organization (PAHO). As surveillance for diseases prevented by new vaccines is integrated into existing surveillance systems, these systems could cost more than routine surveillance for VPDs targeted by the Expanded Program on Immunization.

objectivesWe estimate the costs associated with establishing and subsequently operating the iVPD surveillance system at a pilot site in Costa Rica.

methodsWe retrospectively collected data on costs incurred by the institutions supporting iVPD surveillance during the preparatory (January 2007 through August 2009) and implementation (September 2009 through August 2010) phases of the iVPD surveillance project in Costa Rica. These data were used to estimate costs for personnel, meetings, infrastructure, office equipment and supplies, transportation, and laboratory facilities. Costs incurred by each of the collaborating institutions were also estimated.

resultsDuring the preparatory phase, the estimated total cost was 128,000 U.S. dollars (US$), including 64% for personnel costs. The preparatory phase was supported by CDC and PAHO. The estimated cost for 1 year of implementation was US$ 420,000, including 58% for personnel costs, 28% for laboratory costs, and 14% for meeting, infrastructure, office, and transportation costs combined. The national reference laboratory and the PAHO Costa Rica office incurred 64% of total costs, and other local institutions supporting iVPD surveillance incurred the remaining 36%.

conclusionsCountries planning to implement iVPD surveillance will require adequate investments in human resources, laboratories, data management, reporting, and investigation. Our findings will be valuable for decision makers and donors planning and implementing similar strategies in other countries.

Indexed as

Centers for Disease Control and Prevention, U.S.Costa RicaCosts and Cost AnalysisData CollectionEpidemiological MonitoringHumansImmunization ProgramsPan American Health OrganizationPilot ProjectsPublic Health AdministrationPublic Health SurveillanceRegional Health PlanningUnited StatesVaccinesWorld Health OrganizationVaccines

Identifiers

PMID23777698
PMCPMC4654566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.